The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Johngle I like your analysis but Seingrid point out the thing that metaphorically keeps me up at night that Shanta failed to find a buyer. Any thoughts on why we should be different? Chinese companies are not averse to investing in Africa
I know most of you on this board hate me since I warned the phase 3 trial would likely show only marginal results based on past experience. And others of you think I am a mad old lady who is sad and can’t keep a husband but just in case there is anyone there who is interested
I said the previous trials were essentially repeating what had been done in the past with various other viruses. I had been involved with some of that work.
I have just listened to the interview. If sun groups of patients are to identified by ref to bio markers that would be new and interesting. But please understand this is at present blue sky research . This will be exceptionally challenging and will not be quick.
I find it difficult to see the basis for the 17 million valuation of this company. What exactly is the asset? There is no IP monopoly on interferon and people have been using it since the 1970s, recombinant interferon since 1980s. The clinical trial data does not support commercialisation. Any ideas?
Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554202/#:~:text=Inhaled%20antiviral%20agents%20have%20been,toxicity%20associated%20with%20systemic%20exposure.
No-one said my warnings of caution were reasonable at the time. People were intolerant of my views and abusive. People thought that this technology was new. It is not. It is in my view appropriate to warn people of this. Views that do not conform to the majority are cancelled here it seems